Evaluation of HepaGam B [hepatitis-B-immune-globulin] in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients.

Trial Profile

Evaluation of HepaGam B [hepatitis-B-immune-globulin] in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2013

At a glance

  • Drugs Hepatitis B immune globulin (Primary) ; Adefovir dipivoxil; Antivirals; Lamivudine
  • Indications Hepatitis B
  • Focus Pharmacokinetics
  • Sponsors Cangene Corporation
  • Most Recent Events

    • 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jun 2013 Planned end date changed from 1 Jan 2014 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 17 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top